"Onko-Sure® is a valuable, cost-effective cancer blood biomarker test that has the potential to greatly improve treatment outcomes for colorectal cancer patients," said Douglas MacLellan, Radient Pharmaceuticals Chairman and CEO. "This Presentation provides a broad overview of our anticipated plans for launching a comprehensive national marketing campaign, that is targeted to inform key decision makers, physicians, labs and patients of the importance of incorporating Onko-Sure® into colorectal cancer treatment plans."
"Onko-Sure® The Power of Knowing" is the theme of the presentation. It stresses that this non-invasive and U.S. Food and Drug Administration cleared IVD blood biomarker test is used in the U.S. for monitoring colorectal cancer during and post treatment. Onko-Sure® may also be appropriate for healthy patients who have a predisposition to cancer, family history or are simply vigilant about matters of health and prevention."
Radient Pharmaceuticals' strategy in the U.S., the presentation says, is to sell Onko-Sure® colorectal cancer test kits as a replacement for or in conjunction with Carcionembryonic Antigen (CEA), a cancer tumor marker test. There are five million individual CEA tests performed annually in the U.S. with an approximate value of $250 million. Radient Pharmaceuticals' Advertising & Outreach Plan is designed to assist in capturing a portion of this quarter billion dollar industry marketplace for the Company.
Radient Pharmaceuticals will work in 2012 to provide wide access to Onko-Sure® in key reference labs as well as centers of excellence and cancer treatment centers. It stresses that the Company plans to partner with patient advocacy groups to foster use of Onko-Sure.® The presentation also includes information about the Company's 2012 advertising campaign in journals with high circulation among oncologists and the Company's ongoing outreach platform using its website www.onko-sure.com , Facebook and Twitter. The presentation also introduces key outreach advisors with significant experience in Internet marketing and advertising.
"The presentation explains how Radient Pharmaceuticals will be active in at least five significant medical and laboratory conferences in the U.S. in 2012 and stresses the Company's continuing ability to place scientific abstracts at key meetings of oncologists," Mr. MacLellan said. "The Sales, Advertising and Outreach Plan assumes the Company will have sufficient capital to underwrite its estimated $1.36 million cost."
The new 2012 Sales, Advertising & Outreach Plan Presentation for its Onko-Sure® cancer test kit is available for investors to view at http://radient-pharma.com/pdf/press_releases/2012/Radient%20Outreach%20Plan.pdf